Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Taxes (2023 - 2025)

Historic Change in Taxes for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to $620000.0.

  • Entrada Therapeutics' Change in Taxes rose 13333.33% to $620000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 17245.67%. This contributed to the annual value of -$3.4 million for FY2024, which is 18342.45% down from last year.
  • Entrada Therapeutics' Change in Taxes amounted to $620000.0 in Q3 2025, which was up 13333.33% from -$802000.0 recorded in Q2 2025.
  • Entrada Therapeutics' Change in Taxes' 5-year high stood at $7.4 million during Q2 2023, with a 5-year trough of -$7.4 million in Q3 2023.
  • In the last 3 years, Entrada Therapeutics' Change in Taxes had a median value of -$333500.0 in 2025 and averaged $62000.0.
  • In the last 5 years, Entrada Therapeutics' Change in Taxes plummeted by 13936.38% in 2024 and then soared by 13333.33% in 2025.
  • Over the past 3 years, Entrada Therapeutics' Change in Taxes (Quarter) stood at $4.0 million in 2023, then plummeted by 139.36% to -$1.6 million in 2024, then surged by 139.14% to $620000.0 in 2025.
  • Its Change in Taxes was $620000.0 in Q3 2025, compared to -$802000.0 in Q2 2025 and $135000.0 in Q1 2025.